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Abstract
Prostate cancer is the most frequently diagnosed cancer
in males in the United States, accounting for an
estimated 186,320 new cases in 2008. There are striking
racial or ethnic differences in prostate cancer incidence
and mortality rates in the United States, with Black
males 1.6 times more likely to be diagnosed and 2.4
times more likely to die with prostate cancer than
Whites. Stage at diagnosis is a key prognostic factor
for prostate cancer survival, with African-Americans
generally diagnosed at a more advanced stage. To
identify factors that explain the race-stage disparity in
prostate cancer, we conducted a population-based case-
case study of 251 African-American (46%) and White
(54%) prostate cancer cases diagnosed in Connecticut
between January 1987 and October 1990. Multivariate
logistic regression was used to identify potential
explanatory factors, including clinical, sociodemo-
graphic, medical care, insurance, digital rectal exami-
nation screening history, and lifestyle factors. Cox
proportional hazards models assessed the impact of
study variables on race differences in long-term
survival. Modifiable factors such as screening practice
and sociodemographic factors accounted for >60% of
the race difference in prostate cancer stage at diagnosis.
Histologic grade (Gleason score) accounted for com-
paratively less. Survival analyses confirmed the impor-
tance of tumor characteristics, education, and insurance
in explaining observed race differences in survival.
Although cases were identified before the widespread
use of prostate-specific antigen (PSA) screening, the
results should also be relevant to countries that have
large underserved populations and/or disparities in
access to medical care and cancer screening. (Cancer
Epidemiol Biomarkers Prev 2008;17(10):2825–34)
Introduction
Prostate cancer is the most frequently diagnosed cancer
in males in the United States, with an estimated 186,320
cases to be diagnosed in 2008 (1). With increasing global
development, prostate cancer is an important source of
cancer death, even in developing countries. Worldwide,
3 African countries and 3 Latin American countries
rank among the top 10 countries with the highest
prostate death rates. Although the United States is
ranked 28th with respect to prostate cancer mortality
rates, there are striking racial differences in prostate
cancer incidence and mortality rates among American
men (2, 3). In the United States, for the years 2000 to 2004
(most recent data), the average annual age-adjusted
incidence rates (per 100,000) of prostate cancer were
161.4 in White males and 255.5 in African-American
males. Over the same period, the average annual
age-adjusted mortality rates (per 100,000) for prostate
cancer were 25.6 and 62.3, respectively, for White and
African-American males (3).
Stage at diagnosis is a key predictor of survival from
prostate cancer. Between 1996 and 2003, the 5-year
relative survival rate was 100% among men diagnosed
with prostate cancer at either a localized or regional
stage, but only 32% among men with distant stage
disease (1). In an analysis of National Cancer Institute
Surveillance, Epidemiology and End Results (SEER)
data (4), later stage at diagnosis had the largest impact
on explaining the Black-White difference in prostate
cancer mortality. Although there is a much more
favorable stage distribution in the PSA (prostate specific
antigen) screening era, African-American men are still
somewhat less likely to be diagnosed with localized
prostate cancer compared with White men (89% versus
92%, respectively; ref. 1).
This population-based case-case study was designed
to evaluate race differences in stage at diagnosis
for prostate cancer and to identify factors that
might explain the observed differences. Potential ex-
planatory variables considered in this study included
a wide range of sociodemographic, access to health
care, cancer screening history, clinical, and selected
lifestyle factors. Understanding the role of these factors
in the observed race difference in prostate cancer
stage at diagnosis from a time before PSA screening
may shed light on the smaller but persistent race
difference in prostate stage at diagnosis and survival
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that exists despite widespread prostate cancer screening
in men today.
Materials and Methods
The Study Population. This investigation was part of
a larger study in which race differences in several cancers
that disproportionately burden African-Americans were
investigated. The method was the same for all sites and
has been previously described (5, 6). Between January
1987 and October 1990, using a rapid case-ascertainment
system, we identified all men with newly diagnosed
prostate cancer from the 22 Connecticut hospitals in
which 98% of all African-American cancer cases in
Connecticut were diagnosed. A comparison of African-
American prostate cancer cases ascertained by our
surveillance system to those listed (with some delay) in
the Connecticut Tumor Registry (CTR) (and diagnosed in
these same 22 hospitals) during the study period indicated
that all but 7 prostate cancer cases occurring in African-
American men were identified by our surveillance efforts,
resulting in >98% complete enumeration. Approvals of the
institutional review boards of Yale University School of
Medicine, the State of Connecticut Department of Public
Health, and all participating hospitals have been main-
tained throughout the study period.
Eligibility was limited to men for whom this was a
first malignancy (except nonmelanoma skin cancer)
and who self-identified as African-American or White,
spoke English, and were <80 years old at the time
of diagnosis. Of the 414 eligible men who were
identified, 251 (60.6%) were included in this study
(115 African-American, 136 White). There were no
significant race differences in overall participation
(P = 0.97). However, race was related to reasons for
nonparticipation. Physician refusal to allow contact with
their patients was cited for 16 (21.3%) of 75 African-
American and 35 (39.8%) of 88 White nonparticipants.
Inability to contact occurred for 9 (12.0%) of 75 African-
American nonparticipants compared with 3 (3.4%) of
88 White nonparticipants. There were no significant
differences by race in patient refusal or death occurring
before patient contact (7).
Data Collection. Participants were interviewed in
their homes using a standardized instrument adminis-
tered by trained interviewers. Of the 251 cases, 119
(47.4%), 100 (39.8%), and 32 (2.7%) were interviewed
within 3 months, 3 to 6 months, and >6 months of
their diagnosis, respectively. Time from diagnosis to
interview did not differ by race (P = 0.40) or stage at
diagnosis (P = 0.71). The instrument was a modified
version of the questionnaire used in the National Cancer
Institute’s Black/White Cancer Survival Study (8) and
covered a wide range of variables, including sociodemo-
graphic, health history, medical care, and psychosocial
factors. We abstracted hospital medical records to obtain
complete information on the size and extent of the tumor,
diagnostic work-up, and medical history. With informed
consent obtained at the time of the in-home interview,
photocopies of pathology reports, operative reports,
admission notes, discharge summaries, referral corre-
spondence, and staging reports were obtained. Further
information was obtained when necessary from physi-
cians’ office records.
Stage at Diagnosis. Prostate cancer stage at diagnosis
was assigned to each case independently by two of the
authors (W.L. and R.D.) using the American Urological
Association staging system, the tumor-node-metastasis
staging system established by the American Joint
Committee on Cancer (9), and the SEER Extent of
Disease System (10). Using a systematic process and
detailed medical record search for information on all
diagnostic procedures (including but not limited to a
review of bone scan, CT (Computed Tomography) scan,
and rectal exam results), our reviewers were able to
assign a stage at diagnosis to 25 of 26 cases that were left
unstaged by the Connecticut Tumor Registry (because of
missing data). Only one case was dropped from our
analysis because of the inability to assign a stage at
diagnosis. Differences in interpretation were resolved by
case conference. Based on an evaluation of the impact of
staging criteria on the observed African-American–
White difference in stage at diagnosis using these same
data, we concluded that the American Urological
Association system would provide the most accurate
staging of cases for the purpose of assessing racial
differences (7). Furthermore, the American Urological
Association staging system is consistent with the
Whitmore-Jewett System (11, 12), the system most widely
used at the time of our case enrollment. With minor
differences, it is comparable with the tumor-node-
metastasis staging system that is more common today.
Two notable exceptions in stage at diagnosis assign-
ment include the following: (a) the American Urological
Association system takes elevation of prostatic acid
phosphatase into consideration whereas the tumor-
node-metastasis system does not and (b) the tumor-
node-metastasis system takes into account histologic
grade whereas the American Urological Association
staging system does not. The American Urological
Association staging system defines four stages of
prostate cancer (A, B, C, D). No palpable lesion is
evident in stage A. In stage B, the tumor is confined to
the prostate. In stage C, the tumor is localized to the
periprostatic area. Finally, stage D indicates metastatic
disease. The primary outcome in all analyses is a
dichotomous variable: localized (stages A and B) versus
nonlocalized (stages C and D). This dichotomy has been
associated with substantial differences in survival and
has been used in previous studies (13, 14).
Other Measures. Race, the primary independent
variable, was based on self-identification at the time of
interview; only persons reporting race as Black, African-
American, or White were included in this investigation.
Sociodemographic factors included age (45-64, 65-70, and
71-79 years), marital status (single versus married or
living as married), and three measures of socioeconomic
status: education (1-8, 9-12, and >12 years), occupational
rank based on Duncan’s (15, 16) socioeconomic index
(SEI), (tertiles, 4-20, 21-46, and 47-88), and family income
(<$13,000, $13,000-$24,999, >$24,999). Medical care fac-
tors included having a regular doctor (no, yes), number
of doctor visits (0, z1) over the year before diagnosis,
and usual type of appointment (walk-in, scheduled
appointment). A health care barrier index (high versus
low, where high indicated more barriers) was con-
structed from items that assessed mode of transport-
ation, required transportation time, difficulty in making
Race and Prostate Cancer Stage
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n2 % n2 %
Sociodemographic factors
Age (y)
45-64 31 27.0 25 18.4 2.25 1.16-4.36
65-70 47 40.8 44 32.4 1.93 1.09-3.44
71-79 37 32.2 67 49.3 1.00
Marital status
Single 40 34.5 22 16.2 3.08 1.67-5.68
Living as married 75 65.2 114 83.8 1.00
Education (y)
1-8 42 37.5 17 12.5 17.50 6.98-43.8
9-12 57 50.9 65 47.8 4.50 2.12-9.52
>12 13 11.6 54 39.7 1.00
Occupational rank
Lowest tertile (14-20) 57 50.0 23 16.9 4.79 4.68-20.5
Middle tertile (21-46) 39 34.2 50 36.8 3.01 1.51-6.03
Highest tertile (47-88) 18 15.8 63 46.3 1.00
Family income (US $)
<13,000 27 26.2 15 11.5 6.67 2.86-15.6
13,000-24,999 40 38.8 46 35.1 2.61 1.36-5.03
>24,999 36 35.0 70 53.4 1.00
Medical care factors
Regular doctor
No 25 21.7 11 8.1 2.91 1.35-6.26
Yes 90 78.3 124 91.9 1.00
Number of doctor visits
0 23 20.4 13 9.6 2.52 1.19-5.31
z1 90 79.6 123 90.4 1.00
Appointment type
Walk-in 15 13.5 8 5.9 2.52 1.01-6.28
Scheduled 96 86.5 127 94.1 1.00
Barrier index
High score 68 59.7 57 41.9 2.02 1.20-3.38
Low score 46 40.3 79 58.1 1.00
Understanding of
insurance coverage
Poor 16 15.1 11 8.2 3.46 1.44-8.33
Moderate 51 48.1 43 31.9 2.60 1.47-4.62
Good 39 36.8 81 60.0 1.00
Screening history
DRE
Never 24 21.0 16 11.8 2.24 1.10-4.54
Ever 90 79.0 120 88.2 1.00
Lifestyle factors
Smoking status
Current smoker 25 22.1 22 16.2 1.37 0.76-2.46
Ex-smoker 58 51.3 67 49.3 1.51 0.71-3.21
Never smoker 30 26.6 47 34.5 1.00
Alcohol consumption
Heavy 30 26.6 26 20.0 0.94 0.43-2.04
Light 55 48.7 80 61.5 0.58 0.30-1.12
Never 28 24.8 24 18.5 1.00
BMI
Highest tertile 44 38.6 41 30.2 1.33 0.71-2.49
Middle tertile 35 30.7 49 36.0 0.96 0.51-1.81
Lowest tertile 35 30.7 46 33.8 1.00
Clinical factors
Histologic gradex
Poorly differentiated 29 26.1 24 18.3 1.67 0.89-3.12
Moderate and
well-differentiated
82 73.9 107 81.7 1.00
Comorbid conditions
V3 62 53.9 56 41.2 1.52 0.91-2.53
>3 53 46.1 80 58.8 1.00
Abbreviations: OR, odds ratio; DRE, digital rectal examination.
* See Materials and Methods for definition.
cSample size fluctuates due to missing data.
bAge-adjusted odds ratio, with 95% CI, obtained from multiple logistic regression.
xGleason score 8, 9, 10 (poorly differentiated) versus Gleason score 5, 6, 7 (moderate) and Gleason score 2, 3, 4 (well differentiated).
Cancer Epidemiology, Biomarkers & Prevention
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medical appointments, waiting time for scheduling an
appointment, office waiting time, and satisfaction with
care. Although several questions related to the extent and
quality of health insurance coverage, the only insurance
variables that were effective in discriminating between
patients with different outcomes were those that assessed
the understanding of insurance policy based on two
questions (‘‘has anyone ever explained your insurance
coverage to you or given you something to read about
it?’’ and ‘‘Do you feel that you understand your
insurance coverage or would you like to know more?’’).
Prostate screening history (never versus ever) was
ascertained in reference to digital rectal examination
but not the PSA screening test because this test was not
widely used for screening purposes at this time (17) and
was not available for most of our cohort. Clinical factors
included histologic grade of tumor and comorbidity as
potential explanatory variables. As in the case of stage at
diagnosis, histologic grade was determined by study
investigators (R.D. and W.L.), with differences resolved
by case conference. Using data from pathology reports,
histologic grade was classified using the Gleason
method, dichotomized in these analyses as poorly
differentiated (Gleason score 8, 9, 10) versus moderately
(5, 6, 7) or well-differentiated (2, 3, 4), reflecting the
designations in use at the time of this investigation.
Like the remainder of the potential explanatory
factors, information on comorbidity was elicited from
in-person interview. Using a comorbidity index that
included 25 chronic health conditions, the variable was
categorized as V3 versus >3 comorbid conditions. Body
mass index (BMI) from self-reported usual adult height
and weight was categorized as low, medium, or high
based on tertiles of distribution. (A continuous measure
of BMI and categories that correlate with overweight,
severely overweight, and/or obese were tested and did
not change the reported results.) Lifestyle factors
included smoking status (current or ex-smoker who
smoked regularly for at least 6 months versus never
smoker) and alcohol consumption (heavy, light, and
never, where heavy and light were defined as greater
than or less than the mean, respectively, for those who
reported some consumption in the year preceding their
cancer diagnosis).
Statistical Analysis. Unconditional logistic regression
was the primary tool used for data analysis. Age-
adjusted odds ratios and 95% confidence intervals
(95% CI) are generally reported. Possible explanatory
variables were identified theoretically and empirically.
Based on the existing literature, our a priori assumption
was that screening (digital rectal examination) and
histologic grade would each partially explain the
observed association between race and stage at diagno-
sis. Other explanatory variables were identified empiri-
cally by examining bivariate associations between
candidate variables and race and the outcome variable,
stage at diagnosis, with m2 tests (P < 0.05; not presented)
as well as logistic regression models adjusted only for
continuous age. Analyses stratified by race were done to
determine whether effects on stage at diagnosis were
consistent for African-Americans and Whites.
Variables significantly related to both race and stage at
diagnosis were tested further in age-adjusted models to
assess change in the race-stage odds ratio. Meaningful
change was defined as a 10% change in the estimated
odds ratio for the race-stage association, where the
change-in-estimate is computed as [(adjusted odds
ratio - unadjusted odds ratio) / (unadjusted odds ratio
- 1)]  100 (18).
In a series of models in which digital rectal examina-
tion screening and histologic grade were first introduced
into multivariate models, all variables determined to
have explanatory potential by the methods described
above were tested individually. Entry order presented
in the final model was determined by the relative
contribution of each variable in explaining the age-
adjusted race-stage association in the simpler models.
Adjustment for hospital of diagnosis (n = 22) was not
made to the final models because its inclusion in simpler
models did not substantially alter the reported results.
Finally, Cox proportional hazards regression (hazards
ratios and 95% CI are reported) was used to examine the
role of stage at diagnosis and other factors in observed
race differences in survival from colorectal cancer.
Results
Patient Characteristics by Race. Compared with
Whites in this population-based study of men with
newly diagnosed prostate cancer, African-Americans
were younger, less likely to be married or living as
married, and of lower socioeconomic status (education,
occupational rank, and family income; Table 1). Access to
health care was significantly poorer in African-American
men compared with White men as measured by a single
medical care index (not shown) as well as individual
items, that is, they were less likely to have a regular
doctor, less likely to have visited a doctor in the year
before diagnosis, and less likely to have made an
appointment (versus walk-in) with a doctor’s office
when seeking medical care. African-Americans also
reported a greater number of logistic barriers to receiving
care (e.g., transportation problems, longer wait times
for appointments), and were substantially less likely to
Table 2. Association between race and prostate cancer stage at diagnosis (American Urological Association
staging system): Connecticut 1987 to 1990
Stage at diagnosis* African-American (n = 115) White (n = 136) OR
c
95% CI
n % n %
Nonlocalized 69 60.0 58 42.7 2.02 1.21-3.38
Localized 46 40.0 78 57.4 1.00
*American Urological Association staging system: nonlocalized (stages C and D) versus localized (stages A and B).
cCrude odds ratio, with 95% CI, obtained from logistic regression.
Race and Prostate Cancer Stage
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45-64 29 22.8 27 21.8 1.00 0.52-1.91
65-70 44 34.7 47 37.9 0.87 0.49-1.52
71-79 54 42.5 50 40.3 1.00
Marital status
Single 32 25.2 30 24.2 1.06 0.59-1.87
Living as married 95 74.8 94 75.8 1.00
Education (y)
1-8 37 29.6 22 17.9 2.08 1.01-4.31
9-12 57 45.6 65 52.9 1.03 0.57-1.88
>12 31 24.8 36 29.3 1.00
Occupational rank
Lowest tertile (14-20) 50 39.4 30 24.4 1.99 1.06-3.74
Middle tertile (21-46) 40 31.5 49 39.8 0.98 0.53-1.79
Highest tertile (47-88) 37 29.1 44 35.8 1.00
Family income (US $)
<13,000 21 17.8 21 18.1 1.23 0.59-2.58
13,000-24,999 47 39.8 39 33.6 1.44 0.80-2.60
>24,999 50 42.4 56 48.3 1.00
Medical care factors
Regular doctor
No 23 18.1 13 10.6 1.85 0.89-3.86
Yes 104 81.9 110 89.4 1.00
Number of
doctor visits
0 18 14.2 18 14.8 0.96 0.47-1.94
z1 109 85.8 104 85.2 1.00
Appointment type
Walk-in 12 9.7 15 12.3 0.76 0.32-1.83
Scheduled 112 90.3 107 87.7 1.00
Barrier index
High score 67 53.2 58 46.8 1.28 0.78-2.11
Low score 59 46.8 66 53.2 1.00
Understanding of
insurance coverage
Poor 16 13.3 11 9.1 1.99 0.85-4.66
Moderate 53 44.2 41 33.9 1.75 1.02-3.02
Good 51 42.5 69 57.0 1.00
Screening history
DRE
Never 26 20.6 14 11.3 2.08 1.03-4.21
Ever 100 79.4 110 88.7
Lifestyle factors
Smoking status
Current smoker 25 19.8 22 17.9 0.66 0.31-1.39
Ex-smoker 53 42.1 72 58.5 0.44 0.25-0.79
Never smoker 48 38.1 29 23.6 1.00
Alcohol consumption
Heavy 34 28.1 22 18.0 1.53 0.71-3.29
Light 61 50.4 74 60.7 0.82 0.43-1.57
Never 26 21.5 26 21.3 1.00
BMI
Highest tertile 39 31.0 46 37.1 0.74 0.40-1.36
Middle tertile 44 34.9 40 32.3 0.98 0.53-1.80
Lowest tertile 43 34.1 38 30.7 1.00
Clinical factors
Histologic gradex
Poorly differentiated 43 35.8 10 8.2 6.35 3.04-13.44
Moderate and
well-differentiated
77 64.2 112 91.8 1.00
Comorbid conditions
V3 70 55.1 48 38.7 1.93 1.16-3.22
>3 57 44.9 76 61.3 1.00
* See Materials and Methods for definition.
cSample size fluctuates due to missing data.
bAge-adjusted odds ratio, with 95% CI, obtained from multiple logistic regression.
xGleason score 8, 9, 10 (poorly differentiated) versus Gleason score 5, 6, 7 (moderate) and Gleason score 2, 3, 4 (well differentiated).
Cancer Epidemiology, Biomarkers & Prevention
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report that they were well informed about the extent
of their insurance coverage. A significantly greater
proportion of African-Americans than Whites reported
never having had a screening digital rectal examination.
There were no significant differences between African-
American and White men with respect to lifestyle
factors (smoking, alcohol), BMI, or comorbidity. Com-
pared with 18% of White men, 26% of African-American
men were diagnosed with poorly differentiated tumors
(Gleason score), although this difference was not
statistically significant.
Race Difference in Prostate Stage at Diagnosis.
Consistent with trends reported even in the most recent
SEER registry data (1), racial differences in stage at
diagnosis were observed in our population-based sample
(Table 2). With 69 African-Americans (60.0%) and 58
Whites (42.7%) diagnosed with nonlocalized cancer,
African-Americans were significantly more likely than
Whites to be diagnosed with cancer that had progressed
beyond a localized stage (unadjusted odds ratio = 2.02;
95% CI, 1.21-3.38). One concern was the potential for race
differences in incidental diagnoses of prostate cancer
resulting from possible race differences in transurethral
resection of the prostate for treatment of benign prostatic
hyperplasia. With 22% of cases in African-Americans and
21% in Whites diagnosed with prostate cancer as an
incidental finding (7), this potential source of bias was
dismissed.
Patient Characteristics by Prostate Stage at Diagnosis.
The associations between potential explanatory variables
and stage at diagnosis are shown in Table 3. Those
with nonlocalized and localized prostate cancer were
statistically similar with respect to age, marital status,
family income, health care utilization, lifestyle factors, and
BMI. Patients with nonlocalized disease were substantial-
ly more likely to have lower socioeconomic status based
on education and occupational status, to be less informed
about their insurance coverage, and less likely to have ever
had a screening digital rectal examination.Menwith later-
stage cancers were less likely to report comorbid
conditions in these age-adjusted analyses and consider-
ably more likely (significantly) to have high grade tumors
(odds ratio = 6.35; 95% CI, 3.04-13.44). No statistically
significant interactions with race were identified.
Explaining the Race Difference in Prostate Stage at
Diagnosis. Shown in Table 4 are the changes in estimate
for the age-adjusted race-stage odds ratio after adjusting
Table 4. Relation of race to stage at diagnosis before (model I) and after (model II) adjustment for potential
explanatory variables: Connecticut 1987 to 1990
Explanatory variable* Model
c
OR for race effect
(African-American vs White)
b
95% CI Percentage of change,
estimated ORx
Sociodemographic factors
Marital status (n = 251) I 2.02 1.21-3.38
II 1.98 1.16-2.41 -3.9
Education (n = 249) I 2.00 1.19-3.36
II 1.80 1.02-3.18 -20.0
Occupational rank (n = 250) I 2.06 1.23-3.45
II 1.80 1.03-3.17 -24.5
Family income (n = 234) I 1.73 1.01-2.95
II 1.70 0.97-2.99 -4.1
Medical care factors
Regular doctor (n = 250) I 2.00 1.19-3.35
II 1.89 1.12-3.19 -11.0
Number of doctor visits (n = 249) I 2.12 1.26-3.56
II 2.12 1.26-3.56 -0.0
Barrier index (n = 250) I 1.99 1.19-3.33
II 1.94 1.15-3.27 -5.0
Understanding of insurance coverage (n = 235) I 1.89 1.11-3.19
II 1.69 0.98-2.90 -22.5
Screening history
DRE (n = 250) I 1.98 1.18-3.32
II 1.87 1.11-3.15 -11.2
Lifestyle factors
Smoking status (n = 249) I 2.02 1.21-3.32
II 2.18 1.28-3.71 +15.7
Alcohol consumption (n = 243) I 2.03 1.20-3.42
II 1.96 1.16-3.33 -6.8
BMI (n = 250) I 1.98 1.18-3.32
II 2.04 1.21-3.38 +6.1
Clinical factors
Histologic grade (n = 249) I 2.09 1.24-3.53
II 1.95 1.12-3.40 -12.8
Comorbid conditions (n = 251) I 2.02 1.21-3.38
II 1.93 1.14-3.24 -8.8
* See Materials and Methods for definition.
cModel definitions: I includes race and age as predictors and II includes race, age, and specified explanatory variable as predictors. For each set of models
(I & II), the odds ratio for model I changes slightly to reflect small differences in sample size in the selected explanatory variables.
bAge-adjusted odds ratio, with 95% CI, obtained from multiple logistic regression.
x [(race II odds ratio - race I odds ratio) / (race I odds ratio - 1)]  100.
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for each individual explanatory variable. Among socio-
demographic factors, occupational rank, and education
reduced the odds ratio by >20%. Regarding health care
utilization factors, having a regular doctor resulted in a
meaningful reduction in the odds ratio for the race-stage
association (-11.0%), as did considering oneself to be well
informed about one’s insurance coverage (-22.5%).
Adjustment for screening digital rectal examinations
in the previous 2 years reduced the odds ratio by
11.2%. Of the clinical factors, only histologic grade
showed some explanatory potential, reducing the odds
ratio for race-stage by 12.8%.
In Table 5, we present the model that best explained
the observed race difference in stage at diagnosis based
on the criteria outlined above (Methods, Statistical
Analysis) as well as a conceptual framework in which
it was hypothesized that the observed associations with
stage at diagnosis were likely mediated by either race
differences in screening history or by race differences in
the aggressiveness of the tumor (measured here as
histologic grade). Beginning with a model that reflected
this conceptual framework, adjusting only for age, the
race-stage odds ratio was 1.83 (95% CI, 1.06-3.15).
Adjustment for having ever received digital rectal
examination before diagnosis reduced the race-stage
association by 14.5% (the magnitudes of the changes in
estimate shown here differ slightly from those in Table 4
because of differences in sample size available for
specific analyses). Including histologic grade with digital
rectal examination in the model reduced the odds ratio
by 28.9%. With the addition of education, this odds ratio
was reduced by a total of 58%. Although occupational
ranking looked promising as an explanatory factory from
the unadjusted change-in-estimate models, because of its
strong correlation with education, it was not statistically
significant in the final models. Finally, with the addition
of the variable that measured how well informed these
subjects were about their insurance coverage, the odds
ratio was further reduced. In summary, the race-stage
odds ratio was maximally reduced from 1.83 (95% CI,
1.06-3.15) to 1.21 (95 % CI, 0.64-2.30) when these 4
variables were simultaneously included in the model,
resulting in a 74.7% reduction in the magnitude of the
odds ratio for the race-stage association.
Acknowledging that the likely overlap between factors
that predict histologic grade and those that predict stage
at diagnosis could result in models that are over-
controlled once histologic grade is entered, we also
conducted analyses in which the order of variables
selected into multivariate models was determined by
the relative contribution of each in explaining the race-
stage association. Although this series of models is
not presented, education, insurance, and digital rectal
examination explained 65.4% of the race-stage associa-
tion. The explanatory effect of these factors is comparable
with that described in previous model (74.7%), suggest-
ing a relatively minor role for histologic grade in
explaining the later stage at diagnosis observed in
African-American men.
Prostate Cancer Survival. As a follow-up to this
analysis, we looked at whether tumor characteristics
(stage and grade) alone were responsible for the observed
race differences in long-term survival from colorectal
cancer. Although not presented here, with a maximum of
15 years of follow-up, 70% of the original cohort (n = 175)
had died (all-cause mortality) by 2002. Adjusting only for
their younger age at diagnosis, African-Americans had
significantly poorer survival rates than did Whites
(hazards ratio, 1.53; 95% CI, 1.13-2.08). Adjustment for
more aggressive tumor characteristics (higher stage
and tumor grade) explained some, but not all, of the
race difference in survival (hazards ratio, 1.26; 95% CI,
0.92-1.73). With further adjustment for socioeconomic
status and our insurance measure, we were able to
completely explain the observed race difference in
survival (hazards ratio, 1.03; 95% CI, 0.71-1.49).
Discussion
To the authors’ knowledge, this is one of a few
population-based studies that have systematically
examined explanatory factors for the racial disparity in
stage at diagnosis of prostate cancer. Consistent with
Table 5. Multivariate models explaining the race-prostate cancer stage at diagnosis association: Connecticut 1987
to 1990 (n = 223)
Model Predictor variables* OR
c
95% CI Cumulative percentage of change,
estimated OR
b
I Race 1.83 1.06-3.15
II Race 1.71 0.98-2.97 -14.5
DRE 1.91 0.88-4.16
III Race 1.59 0.88-2.86 -28.9
DRE 2.24 0.99-5.03
Histologic grade 6.04 2.79-13.07
IV Race 1.36 0.73-2.55 -58.0
DRE 2.00 0.88-4.57
Histologic grade 5.90 2.72-12.81
Education 1.77 0.82-3.82
V Race 1.21 0.64-2.30 -74.7
DRE 1.93 0.84-4.43
Histologic grade 5.90 2.71-12.86
Education 1.78 0.82-3.87
Understanding of insurance coverage 1.65 0.91-2.99
* See Materials and Methods for definition.
cAge- and specified variable –adjusted odds ratio, with 95% CI, obtained from multiple logistic regression.
b[(fully adjusted odds ratio - race + age odds ratio)/(race + age odds ratio - 1)]  100.
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previous work (20-26), we observed that African-Amer-
icans were twice as likely as Whites to be diagnosed at a
more advanced stage of disease. We also observed that
African-Americans were disadvantaged in terms of
survival.
Unlike other studies (22, 23), the current study was
able to explain more than half of the observed race
difference in stage at diagnosis, rendering it not
statistically significant. However, adjustment for indi-
vidual explanatory factors produced relatively modest
modifications of the race-stage association, indicating
that this is a complex relationship that cannot be
explained by any single factor. Although adjustment
for a few variables reduced the association to non-
significance, our goal was to identify the set of variables
that could maximally reduce the stage difference
between African-American and White men. By account-
ing for racial differences in use of screening digital rectal
examination, histologic grade of tumors, level of educa-
tion, and the degree to which men are informed about
their insurance coverage, we were able to explain up to
75% of the excess risk for late stage at diagnosis of
prostate cancer in African-American compared with
White men. Although we cannot rule out missed
associations secondary to limited statistical power, we
were able to rule out an explanatory role for obesity and
smoking history, both of which have been reported to be
associated with advanced or fatal prostate cancer in a
large cohort study (27). We also ruled out multiple
measures of access to and previous medical care as well
as alcohol consumption. Although more aggressive
prostate cancer has been associated with a positive
family history (27), we could not assess this variable in
this study because only seven African-Americans
reported prostate cancer in any male relative.
Because low socioeconomic status is known to impact
access to care and is also more common in African-
Americans, socioeconomic factors have been hypothe-
sized to explain the observed racial difference in stage at
diagnosis for prostate cancer. We observed that educa-
tion level had a meaningful impact on the race-stage
relation, but consistent with previous reports (21-24, 28),
adjustments for race differences in education level
did not entirely explain the stage disparity. Despite
the availability of a number of factors hypothesized
to mediate the effect of education (e.g., medical care
and lifestyle factors), we were unable to identify the
precise mechanism through which education operates.
One potential pathway could include a mediating
role for nutritional factors. Although much of this
work has considered the role of diet on prostate
cancer risk, some work has shown a link between
dietary fat (29-33), caloric intake (27), and a-linolenic
acid (27, 34, 35) and advanced prostate cancer. Recent
reports from one of these groups have shown tomato
sauce consumption to be protective against advanced
and fatal prostate cancer (27, 36). Although it is likely
that the effect of nutritional and dietary factors is
mediated by hormones and other growth factors, it
is also possible that genetic polymorphisms play a
role in the development of an aggressive phenotype
(27, 37). Acknowledging the likelihood of substantial
race differences in selected nutritional factors, and
possibly the prevalence of selected genetic polymor-
phisms, we were not able to explore these pathways
because neither dietary data nor blood samples were
collected in this investigation.
Understanding one’s insurance coverage, but none
of the actual health care utilization variables, had an
impact on the association between race and stage at
diagnosis in a multivariate context. Other support for the
importance of insurance comes from a study by Conlisk
et al. (38), in which an association between stage and
health insurance status was observed, but only among
African-American men. Of note, we collected informa-
tion on whether participants had insurance and type of
insurance, but the only important explanatory variable
was the one that assessed the degree to which an
individual was informed about their insurance coverage.
This variable likely reflects both access to care and
familiarity, and, possibly, comfort level with using the
health care system, suggesting that insurance coverage
alone may not be sufficient to ensure improved health
outcomes. Support for this interpretation comes from a
Veterans Affairs Medical Centers study, a setting in
which access to care is theoretically equalized, and
insurance and other financial barriers to screening and
medical care are minimized or eliminated. In that study,
African-American men were still more likely to be
diagnosed with distant-stage cancer and to have poorer
survival than White men (26).
Conceptually, of the extensive socioeconomic and
medical care factors considered, prostate cancer screen-
ing was expected to play an important role in explaining
the race stage at prostate cancer diagnosis association.
Ever having had a screening digital rectal examination
before diagnosis had a meaningful impact on the race-
stage association, yet the measured impact was not as
large as anticipated (11.2%). It is interesting to note that
this finding of a relatively minor explanatory effect of
screening digital rectal examination is similar to results
reported for breast cancer patients enrolled in this same
study. In that analysis, adjustment for mammography
screening accounted for only 9.2% of the racial difference
in stage at diagnosis of breast cancer (5). As has been
suggested in the case of breast cancer, there may be racial
differences in the benefits received from the same
screening procedures that relate to systematic differences
in patient tracking and follow-up care for positive
screening tests (39-41).
A comparison of the two approaches used in
multivariate modeling confirms the explanatory impor-
tance of socioeconomic, insurance, and medical factors.
However, the effect of histologic grade, a measure of
tumor differentiation, on the race difference in stage at
diagnosis was somewhat limited once these other
variables were in the model. This may be due in part to
the lack of a statistically significant difference in the
proportion of poorly differentiated tumors between
African-Americans and Whites, as has been reported by
others (25).
Together, socioeconomic factors, understanding of
health insurance, and screening history factors played a
substantial explanatory role in the later stage at diagnosis
in African-American compared with White men. Al-
though racial disparities in socioeconomic status and
insurance (however measured) have persisted in the
years since this cohort was diagnosed, a substantial
change in prostate screening has occurred, with the
now widespread use of PSA testing in the United States
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and other developed countries. As noted earlier, prostate
screening at the time of the enrollment of our study
subjects was primarily limited to digital rectal examina-
tion. An analysis based on a sample of men enrolled in
Medicare showed that no more than 2% of White men
and 1% of Black men aged 65 years and older were
receiving PSA testing 1 year into our study enrollment,
and 6% or fewer African-American men (and slightly
more White men) received this test in 1990, the last year
of our enrollment (42).
Changes in the distribution of stage at diagnosis have
also occurred since the time of our study enrollment,
much of it attributable to increased PSA screening.
Whereas estimates based on SEER data for 1974 to 1985
show that approximately 21% (Blacks, 25.4%; Whites,
20.4%) of all prostate cancer cases were diagnosed at a
distant stage, the most recent data show that only 5% of
all cases (African-Americans, 6%; Whites, 4%) were
diagnosed with distant-stage prostate cancer (1). Assum-
ing that factors that influenced digital rectal examination
screening are similar to those that influence PSA
screening, these results, taken together with race differ-
ences in education and familiarity with insurance
coverage in explaining the race-stage association, under-
score the need for a more active role on the part of health
care systems to improve access to care and screening
(and presumably, timely and appropriate follow-up to
ensure maximum benefit from screening) in traditionally
underserved populations. Furthermore, our results may
have important implications for health care in countries
in which digital rectal examination, rather than PSA
testing, is the primary screening tool or in which there
are subpopulations that are traditionally underserved by
the existing health care system.
As in all retrospective studies, potential limitations
include the possibility of recall bias. This should be
minimized in the current study because cases were
compared with cases and not controls. Similarly, sub-
stantial detection bias is unlikely because the compar-
isons made to registry data (one of the SEER sites)
showed virtually identical stage distribution between
study participants and nonparticipants, that is, 58% of
White and 47% of African-American nonparticipants
were diagnosed with localized prostate cancer compared
with 59% of White and 47% of African-American study
participants (7). In addition, information on method of
diagnosis was ascertained (e.g., transurethral resection of
the prostate) and did not differ across race groups.
Unequal diagnostic evaluation is also unlikely to be a
factor in stage assignment between the race groups
because extent of diagnostic evaluation (such as lymph
node examination or bone scan) was comparable among
African-Americans and Whites. Finally, although there
was some variation among cases in time lapsed between
diagnosis and interview, potentially introducing vari-
ability in the quality of interview information, any
resulting misclassification would have been nondiffer-
ential with respect to race because the period from
diagnosis to interview did not vary by race or stage at
diagnosis.
These potential limitations are balanced by the many
strengths of the study. First, it was population-based,
with near-complete coverage of all prostate cancer cases
in Connecticut. Second, compared with some other
population-based interview studies, we had a relatively
large number of African-American prostate cancer cases,
thus increasing statistical power. Third, many past
studies derived their information on stage at diagnosis
from tumor registries rather than standardized review.
Liu et al. (7) found that approximately 23% of prostate
cancers in the CTR were incorrectly staged. The current
study corrected such errors by making use of a
standardized protocol for the staging of cases done by
study physicians who were blinded to patient informa-
tion. Fourth, in-person interviews were conducted using
a comprehensive instrument to obtain information on a
wide range of potential explanatory variables not usually
collected in hospital- or registry-based studies. Finally,
by linking our data to survival information, we were able
to confirm the importance of the variables studied here
on race differences in survival. We showed that race
differences in stage at diagnosis and tumor grade
contributed significantly to the race differences in
prostate cancer survival. However, it was not until we
accounted for their disadvantage with respect to socio-
economic status and insurance coverage that we were
able to fully explain the poorer observed survival in
African-American compared with White men.
Conclusions. These results suggest that the disadvan-
tage with respect to stage at diagnosis of prostate cancer
observed in African-American men compared with
White men reflected racial disparities in socioeconomic
status and access to health care more than strong
biological differences and are therefore potentially
mutable. Identification of these causal pathways is
especially important for the goal of developing inter-
ventions to reduce or eliminate the race difference in
prostate cancer stage at diagnosis and survival. Contin-
ued efforts to improve access to care, insurance coverage,
and prostate screening in African-American men, partic-
ularly now that the PSA screening test is widely
available, may lessen race differences in morbidity and
mortality substantially. Although these cases were
identified before the widespread use of PSA screening,
the results may also be relevant to countries that have
large underserved populations and/or disparities in
access to medical care and cancer screening.
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